Literature DB >> 3358278

Reversibility of cyclosporine-induced hypoandrogenism in rats.

S C Sikka1, M A Koyle, R S Swerdloff, J Rajfer.   

Abstract

In an attempt to determine whether the inhibition of the hypothalamic-pituitary-testicular axis induced by oral cyclosporine (CsA) is reversible, intact adult male rats were treated with 30 mg/kg oral CsA daily for 4 weeks, and then vehicle (orange juice) for the next 4 weeks. A second group of animals (control) was fed orange juice throughout the entire 8 weeks of the experiment. Serum testosterone (T) was decreased significantly (P less than 0.01) after 4 weeks of CsA treatment when compared with controls. After cessation of oral CsA for the next 4 weeks, there was no difference in serum T between the control and CsA-treated groups. Serum LH, intratesticular T, ventral prostate (VP) and seminal vesicle (SV) weights paralleled the serum T levels at 4 and 8 weeks--i.e., all values were decreased in the 4-week CsA-treated group when compared with controls, and these returned to normal at 8 weeks. Intratesticular 17 alpha-hydroxylase and 17,20-desmolase activities were significantly lower after 4 weeks of CsA treatment; following cessation of the CsA, these enzymatic values returned to normal within 4 weeks. These data demonstrate that at the duration of treatment and the dose studied, the CsA-induced inhibition of the hypothalamic-pituitary-testicular axis of the intact adult rat is completely reversible.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3358278     DOI: 10.1097/00007890-198804000-00023

Source DB:  PubMed          Journal:  Transplantation        ISSN: 0041-1337            Impact factor:   4.939


  2 in total

1.  Cyclosporine is angiostatic.

Authors:  K Norrby
Journal:  Experientia       Date:  1992-12-01

Review 2.  Endocrine and metabolic abnormalities following kidney transplantation.

Authors:  W H Hörl; W Riegel; C Wanner; M Haag-Weber; P Schollmeyer; H Wieland; H Wilms
Journal:  Klin Wochenschr       Date:  1989-09-01
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.